N2,N2-dimethylbenzothiazole-2,5-diamine | 813424-15-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: N2,N2-dimethylbenzothiazole-2,5-diamine
• 英文别名: N2,N2-Dimethylbenzo[d]thiazole-2,5-diamine；2-N,2-N-dimethyl-1,3-benzothiazole-2,5-diamine
• CAS: 813424-15-6
• 化学式: C₉H₁₁N₃S
• 分子量: 193.272
• InChiKey: NPUGFFFHAQKONQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  70.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N2,N2-dimethylbenzothiazole-2,5-diamine 、 6-(4-fluorophenyl)-2-methyl-3-pyridinecarboxylic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-[2-(dimethylamino)-1,3-benzothiazol-5-yl]-6-(4-fluorophenyl)-2-methylpyridine-3-carboxamide
  参考文献：
  名称：

  Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1

  摘要：

  6-Phenylnicotinamide (2) was previously identified as a potent TRPV1 antagonist with activity in an in vivo model of inflammatory pain. Optimization of this lead through modi. cation of both the biaryl and heteroaryl components has resulted in the discovery of 6-(4-fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl) nicotinamide (32; SB-782443) which possesses an excellent overall pro. le and has been progressed into pre-clinical development. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.105
• 作为产物：
  描述：

  5-nitro-N,N-dimethyl-2-benzothiazolamine 、 1,3-苯并噻唑-5-胺 生成 N2,N2-dimethylbenzothiazole-2,5-diamine
  参考文献：
  名称：

  Compounds and methods of use

  摘要：

  所选化合物对于预防和治疗血管生成介导的疾病等疾病有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗癌症等涉及疾病和其他疾病或病况的方法。该发明还涉及制造这种化合物的过程以及在这种过程中有用的中间体。

  公开号：

  US20070185171A1

文献信息

• [EN] NADPH OXIDASE 4 INHIBITORS<br/>[FR] INHIBITEURS DE LA NADPH OXYDASE 4
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2016207785A1

  公开（公告）日：2016-12-29

  The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.

  该发明涉及Formula (I)的2,5-二取代苯并噁唑和苯并噻唑衍生物，其中L、X、Y和环(A)如描述中所述，它们的制备以及它们作为药用活性化合物的用途。这些化合物可能对预防或治疗与受损的活性氧自由基（ROS）产生相关的疾病或紊乱，以及预防或治疗各种纤维化疾病具有用处。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：METHYLGENE INC

  公开号：WO2004069823A1

  公开（公告）日：2004-08-19

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  该发明涉及抑制组蛋白去乙酰化酶的技术。该发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。
• Compounds and methods of use
  申请人：Germain Julie

  公开号：US20070185171A1

  公开（公告）日：2007-08-09

  Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗血管生成介导的疾病等疾病有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗癌症等涉及疾病和其他疾病或病况的方法。该发明还涉及制造这种化合物的过程以及在这种过程中有用的中间体。
• NADPH oxidase 4 inhibitors
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US10584118B2

  公开（公告）日：2020-03-10

  The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.

  本发明涉及式 (I) 的 2,5-二取代苯并恶唑和苯并噻唑衍生物 其中 L、X、Y 和环（A）如描述中所述，它们的制备及其作为药用活性化合物的用途。所述化合物可用于预防或治疗与活性氧（ROS）生成受损有关的疾病或紊乱，和/或预防或治疗各种纤维化疾病。
• BENZAMIDE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP1632477B1

  公开（公告）日：2017-03-01